Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Zoryve
Generic Name
Roflumilast
Active Ingredient
RoflumilastCategory
Phosphodiesterase 4 Inhibitor [EPC]
Variants
4
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Zoryve, you must consult a qualified healthcare professional.
| 3 mg/g | AEROSOL, FOAM | TOPICAL | 80610-430 |
Detailed information about Zoryve
Roflumilast is a potent selective phosphodiesterase 4 (PDE4) inhibitor used to reduce the risk of COPD exacerbations and treat inflammatory skin conditions like plaque psoriasis.
For the management of Chronic Obstructive Pulmonary Disease (COPD), the standard maintenance dose of roflumilast is 500 mcg taken orally once daily. To improve tolerability and reduce the incidence of gastrointestinal side effects, healthcare providers often initiate treatment with a starting dose of 250 mcg once daily for the first 4 weeks, followed by an increase to the 500 mcg maintenance dose. This titration period is crucial for helping the body adjust to the medication.
For Plaque Psoriasis, the 0.3% cream is typically applied to affected areas once daily. It is important to apply a thin layer and rub it in completely. The cream can be used on most areas of the body, including the face and skin folds, which are often sensitive to traditional topical steroids.
For Seborrheic Dermatitis, the 0.15% foam is applied once daily to the affected skin and/or scalp. Patients should ensure the area is dry before application.
Oral roflumilast is not approved for use in pediatric patients. Its safety and efficacy in individuals under 18 years of age for COPD have not been established.
Topical roflumilast (Zoryve) is approved for pediatric use in specific age groups:
No dosage adjustment is generally required for patients with renal impairment. Clinical studies indicate that the pharmacokinetics of roflumilast and its active metabolite are not significantly altered by varying degrees of kidney function, including those on dialysis.
Roflumilast is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). For patients with mild hepatic impairment (Child-Pugh Class A), healthcare providers should exercise extreme caution, as the exposure to the drug may be increased, leading to a higher risk of adverse effects.
No specific dose adjustments are required for elderly patients based on age alone. However, since older adults are more prone to significant weight loss and may have underlying hepatic or renal issues, they should be monitored closely for side effects and changes in body weight.
If you miss a dose of roflumilast, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed one. Consistency is key to maintaining the therapeutic levels of the drug in your system.
Signs of an acute overdose may include severe headache, gastrointestinal upset (nausea, vomiting, diarrhea), dizziness, palpitations, and lightheadedness. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for roflumilast; treatment is primarily supportive and focused on managing symptoms.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a return of symptoms or increased risk of exacerbations.
Side effects are most common during the first few weeks of treatment and often diminish as the body acclimates to the medication. The most frequently reported adverse reactions include:
Roflumilast is a potent anti-inflammatory agent that requires careful patient selection. It is specifically indicated for the maintenance treatment of severe COPD and is not a bronchodilator. It should never be used as a rescue medication for acute breathing difficulties (bronchospasm). Patients must continue to have access to their short-acting beta-agonists (SABA) for emergency use.
No FDA black box warnings for Roflumilast. However, the medication is categorized with high-level precautions regarding psychiatric health and metabolic changes.
Roflumilast is categorized as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies of roflumilast in pregnant women. Animal studies have shown evidence of embryo-fetal toxicity, including reduced fetal weight and skeletal retardations at doses significantly higher than the human therapeutic dose. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is generally not recommended for use during labor and delivery, as PDE4 inhibitors can theoretically interfere with uterine contractions.
It is not known whether roflumilast or its metabolites are excreted in human milk. However, studies in lactating rats have shown that the drug is present in animal milk. Because of the potential for serious adverse reactions in nursing infants (such as weight loss and psychiatric irritability), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Roflumilast is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). PDE4 is the dominant cAMP-metabolizing enzyme in inflammatory cells, including neutrophils, macrophages, and T-lymphocytes. By inhibiting PDE4, roflumilast increases intracellular levels of cyclic AMP (cAMP). This increase in cAMP leads to the suppression of inflammatory cell activity and the inhibition of the release of pro-inflammatory cytokines such as TNF-α and leukotriene B4. In the lungs, this reduces airway inflammation; in the skin, it reduces the hyperproliferation of keratinocytes and the infiltration of inflammatory cells.
The pharmacodynamic effect of roflumilast is characterized by a reduction in inflammatory markers. In patients with COPD, roflumilast has been shown to reduce the number of neutrophils and eosinophils in sputum. The onset of the clinical effect is slow, often taking several weeks to reach full therapeutic potential. It does not possess direct bronchodilatory activity and therefore does not provide immediate relief of airflow obstruction.
| Parameter | Value |
Common questions about Zoryve
Roflumilast is primarily used as a maintenance treatment to reduce the frequency of flare-ups, or exacerbations, in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis. It is specifically intended for those who have a history of frequent exacerbations despite using other therapies. In addition to its oral use for lung health, a topical cream version is FDA-approved to treat plaque psoriasis and seborrheic dermatitis in adults and children. It works by targeting the underlying inflammation rather than just relaxing the airways or masking skin symptoms. Because it is not a bronchodilator, it should never be used for the emergency treatment of sudden breathing problems. Your doctor will determine the best form and dose based on your specific inflammatory condition.
The most common side effects associated with oral roflumilast include diarrhea, nausea, and significant weight loss. These symptoms typically appear within the first few weeks of starting the medication and may decrease over time as your body adjusts. Other frequent issues include headache, insomnia, and a decreased appetite. For the topical cream version, common side effects are much milder and usually limited to application site reactions like stinging or redness. It is important to monitor your weight and mood closely while taking the oral tablets. If any side effect becomes severe or persistent, you should contact your healthcare provider immediately to discuss whether the medication is still appropriate for you.
There is no known direct chemical interaction between roflumilast and alcohol that would make moderate drinking strictly forbidden. However, both substances can cause dizziness and gastrointestinal upset, so combining them might make these side effects feel more intense. Furthermore, roflumilast is processed by the liver, and heavy alcohol consumption can stress the liver, potentially affecting how the drug is metabolized. If you have a history of liver disease, you should be especially cautious about alcohol use while on this medication. It is always best to discuss your alcohol consumption habits with your doctor to ensure it doesn't interfere with your COPD or psoriasis management plan. Most healthcare providers recommend moderation to avoid complicating the drug's side effect profile.
Roflumilast is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. It is classified as Pregnancy Category C, meaning animal studies have shown some potential for harm, but there are no comprehensive studies in humans. Specifically, animal data suggests it could lead to lower birth weights or skeletal issues at high doses. There is also a theoretical concern that it could interfere with labor and delivery by affecting uterine contractions. If you are pregnant or planning to become pregnant, you must discuss alternative treatments with your healthcare provider. Breastfeeding is also discouraged while taking the oral form because the drug may pass into breast milk and affect the infant's growth and development.
Roflumilast is a long-term maintenance medication and does not provide immediate relief of symptoms. For patients with COPD, it may take several weeks or even a few months of daily use before a significant reduction in the frequency of flare-ups is noticed. In clinical trials, improvements in lung function were often measured after 4 to 8 weeks of consistent therapy. For the topical cream used in psoriasis, many patients begin to see an improvement in skin redness and scaling within the first two weeks, but maximum results often take 8 weeks or longer. It is vital to continue taking or applying the medication exactly as prescribed, even if you do not feel better right away. Stopping the medication prematurely can lead to a return of symptoms.
While roflumilast does not cause a physical 'withdrawal' syndrome in the way that some other medications do, you should not stop taking it suddenly without consulting your doctor. Discontinuing the medication will stop the anti-inflammatory protection it provides, which could lead to an increase in COPD exacerbations or a flare-up of your psoriasis. If you are experiencing bothersome side effects like severe diarrhea or mood changes, your doctor may suggest a different dosing schedule or a different medication entirely. Always talk to your healthcare provider before making any changes to your prescription regimen. They will help you weigh the benefits of the drug against the side effects you are experiencing. If you do stop, your doctor will likely want to monitor your condition closely for any worsening of symptoms.
If you miss a dose of roflumilast, you should take it as soon as you remember on that same day. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply take the next one at your regular time. You should never take two doses at once to make up for a missed one, as this can significantly increase your risk of side effects like nausea and diarrhea. To help you remember your dose, try taking it at the same time every day, perhaps with breakfast or before bed. If you find yourself frequently missing doses, consider using a pill organizer or a smartphone reminder app. Consistent daily dosing is necessary for the medication to effectively control inflammation.
No, roflumilast is actually associated with weight loss rather than weight gain. In clinical trials, a significant number of patients taking the oral tablets experienced a decrease in body weight, averaging between 5 and 10 pounds over the course of a year. This weight loss is thought to be a direct effect of the PDE4 inhibition on metabolism and appetite. For some patients, this weight loss can be severe or undesirable, especially if they are already thin. Because of this, healthcare providers recommend regular weight monitoring during treatment. If you notice a rapid or unexplained drop in weight, you should report it to your doctor immediately. They will evaluate whether the weight loss is harmful and if you should continue the medication.
Roflumilast can interact with several other medications, particularly those that affect liver enzymes. For example, strong liver enzyme inducers like rifampin or carbamazepine can make roflumilast much less effective. On the other hand, certain antidepressants like fluvoxamine can increase the levels of roflumilast in your blood, making side effects more likely. It is generally safe to take with most common COPD inhalers, such as tiotropium or salmeterol, as they work through different mechanisms. However, you must provide your doctor with a complete list of all the medicines, vitamins, and herbal supplements you use. This allows them to check for potential interactions and ensure that roflumilast is a safe addition to your current treatment plan.
Yes, roflumilast is available as a generic medication for the oral tablet formulation. The generic version was approved by the FDA in recent years, providing a more cost-effective option for patients with COPD who were previously using the brand-name drug Daliresp. Generic medications are required to have the same active ingredient, strength, and effectiveness as the brand-name versions. However, the topical cream (Zoryve) is a newer product and may not yet be available in a generic form in all regions. You should check with your pharmacist and insurance provider to see which version is covered under your plan. Using the generic version of the tablets can significantly reduce out-of-pocket costs for long-term maintenance therapy.
Other drugs with the same active ingredient (Roflumilast)
> Warning: Stop taking Roflumilast and call your doctor immediately if you experience any of these symptoms.
Long-term use of roflumilast (over several years) has been studied in clinical trials like the M2-124 and M2-125 studies. The primary long-term concern is the maintenance of body weight and the monitoring of mental health. There is no evidence that roflumilast causes long-term immunosuppression, which is a benefit compared to chronic corticosteroid use. However, patients should remain under regular medical supervision to monitor for any delayed psychiatric or metabolic changes.
There are no FDA black box warnings for roflumilast as of 2024. However, the FDA-approved labeling contains significant warnings regarding psychiatric events and weight loss that carry nearly the same clinical weight in practice. Healthcare providers are instructed to carefully weigh the risks and benefits in patients with a history of depression or suicidal behavior.
Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.
Roflumilast generally does not impair the ability to drive or operate machinery. However, if you experience dizziness or tremors as a side effect, you should avoid these activities until you are certain the medication does not affect your performance.
There is no direct contraindication for alcohol use with roflumilast. However, alcohol can exacerbate certain side effects like dizziness and nausea. Furthermore, chronic heavy alcohol use can impair liver function, which may affect how the body processes roflumilast.
There is no evidence of a withdrawal syndrome or a need for a tapering schedule when stopping roflumilast. However, you should not stop the medication without consulting your doctor, as your COPD symptoms or skin condition may worsen upon discontinuation.
> Important: Discuss all your medical conditions, especially any history of liver disease or depression, with your healthcare provider before starting Roflumilast.
Roflumilast is not known to interfere significantly with common laboratory tests, including blood chemistry, hematology, or urinalysis. However, always inform your laboratory technician and doctor of all medications you are taking.
Most interactions with roflumilast occur through the Cytochrome P450 (CYP) enzyme system. Because roflumilast must be converted to its active N-oxide metabolite by CYP3A4 and CYP1A2, any drug that speeds up (induces) or slows down (inhibits) these enzymes will change the balance of the parent drug and the active metabolite in the bloodstream. This can result in either reduced efficacy (if the drug is cleared too fast) or increased toxicity (if the drug builds up).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.
There is no established cross-sensitivity between roflumilast and other classes of respiratory medications (like beta-agonists or anticholinergics) or other dermatological agents. However, patients who have had reactions to other PDE4 inhibitors (like apremilast or crisaborole) should be monitored closely, as they may share similar sensitivities to the mechanism of action or chemical structure.
> Important: Your healthcare provider will evaluate your complete medical history, including liver function and mental health status, before prescribing Roflumilast.
In clinical trials, no overall differences in safety or effectiveness were observed between elderly patients (65 years and older) and younger patients. However, elderly patients may be more sensitive to the weight loss side effects. Given that many elderly COPD patients are already at risk for sarcopenia (muscle loss), regular weight checks are essential. No dose adjustment is required based solely on age.
The pharmacokinetics of roflumilast are not significantly affected by renal impairment. No dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment. This includes patients with end-stage renal disease (ESRD) on hemodialysis.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safest possible therapeutic outcome.
| Bioavailability | ~80% |
| Protein Binding | ~99% (Albumin) |
| Half-life (Parent) | ~17 hours |
| Half-life (N-oxide) | ~30 hours |
| Tmax | ~1 hour (Fasted) |
| Metabolism | CYP3A4, CYP1A2 |
| Excretion | Renal 70%, Fecal 20% |
Roflumilast is the first and currently only oral PDE4 inhibitor approved for COPD. It is related to other PDE4 inhibitors like apremilast (used for psoriatic arthritis) and crisaborole (a topical treatment for atopic dermatitis). Within the respiratory field, it is classified as a non-steroidal anti-inflammatory maintenance agent.